RxSight (NASDAQ:RXST) Given "Neutral" Rating at BTIG Research

RxSight (NASDAQ:RXST - Get Free Report)'s stock had its "neutral" rating reissued by stock analysts at BTIG Research in a research report issued on Wednesday, Marketbeat reports.

Other analysts have also issued research reports about the company. Needham & Company LLC reissued a "buy" rating and set a $43.00 price objective on shares of RxSight in a report on Thursday, April 3rd. JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $17.00 price objective (down previously from $40.00) on shares of RxSight in a research report on Friday, April 4th. Stifel Nicolaus dropped their target price on RxSight from $33.00 to $28.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Wells Fargo & Company upgraded RxSight from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $17.00 to $25.00 in a report on Monday, May 19th. Finally, Bank of America reiterated an "underperform" rating and issued a $22.00 price objective (down previously from $36.00) on shares of RxSight in a report on Thursday, April 3rd. Two analysts have rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $30.20.

RxSight Trading Down 37.8%

NASDAQ RXST traded down $4.84 during trading on Wednesday, reaching $7.95. 16,719,904 shares of the company's stock were exchanged, compared to its average volume of 787,362. RxSight has a fifty-two week low of $6.29 and a fifty-two week high of $58.23. The firm has a market capitalization of $323.09 million, a PE ratio of -11.87 and a beta of 1.21. The company's fifty day simple moving average is $14.40 and its 200-day simple moving average is $22.48.

RxSight (NASDAQ:RXST - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.03) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.03). The business had revenue of $37.90 million for the quarter, compared to the consensus estimate of $38.74 million. RxSight had a negative return on equity of 9.54% and a negative net margin of 17.90%. The firm's revenue was up 28.5% compared to the same quarter last year. During the same period last year, the business earned ($0.25) EPS. Equities analysts forecast that RxSight will post -0.7 EPS for the current fiscal year.

Institutional Trading of RxSight

A number of hedge funds have recently added to or reduced their stakes in RXST. Mountain Capital Investment Advisors Inc. raised its stake in shares of RxSight by 3.8% during the fourth quarter. Mountain Capital Investment Advisors Inc. now owns 8,779 shares of the company's stock valued at $302,000 after acquiring an additional 320 shares during the last quarter. Wells Fargo & Company MN increased its holdings in RxSight by 1.7% during the 4th quarter. Wells Fargo & Company MN now owns 26,574 shares of the company's stock worth $914,000 after purchasing an additional 445 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of RxSight by 1.2% in the fourth quarter. Legal & General Group Plc now owns 42,445 shares of the company's stock valued at $1,459,000 after acquiring an additional 512 shares in the last quarter. F M Investments LLC lifted its position in shares of RxSight by 12.6% during the 4th quarter. F M Investments LLC now owns 5,901 shares of the company's stock valued at $203,000 after buying an additional 659 shares during the last quarter. Finally, Coppell Advisory Solutions LLC lifted its position in shares of RxSight by 108.9% during the 4th quarter. Coppell Advisory Solutions LLC now owns 1,289 shares of the company's stock valued at $44,000 after buying an additional 672 shares during the last quarter. Institutional investors and hedge funds own 78.78% of the company's stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.